Based on these results of univariate and multivariate analyses, we can identify the patients’ factors which are related to benefits of longer survival: initial better performance status and laboratory test results (especially normal albumin level), primary tumor genotype (exon 11 KIT mutants and genotype other than exon 18 PDGFRA D842V), the smaller maximal size of the largest tumor, and resection of residual disease during imatinib therapy. Here, ALB is linked to neoplasm.